Thielsen T, Frerker C, Schmidt T, Schlüter M, Kreidel F, Alessandrini H, Kuck K-H
Abteilung für Kardiologie, II. Medizinische Klinik, Asklepios Klinik St. Georg, Lohmühlenstr. 5, 20099, Hamburg, Deutschland.
Asklepios proresearch, Hamburg, Deutschland.
Internist (Berl). 2016 Apr;57(4):341-8. doi: 10.1007/s00108-016-0029-7.
Percutaneous valve therapies represent one of the most innovative areas within interventional cardiology in the past 10 years.
The aim of this work is to give an overview of current and upcoming therapeutic options.
In this manuscript, the results of a retro- and prospective literature research are summarized.
With the introduction of percutaneous therapies for valvular heart disease, patients who were previously considered too ill for surgery can now be treated. The percutaneous treatment of aortic or mitral valve disease has become standard therapy. Likewise, promising results have been obtained for percutaneous treatment options for pathologies of the tricuspid valve, which are still under intense investigation.
经皮瓣膜治疗是过去10年介入心脏病学领域最具创新性的领域之一。
本研究旨在概述当前及未来的治疗选择。
本文总结了回顾性和前瞻性文献研究的结果。
随着瓣膜性心脏病经皮治疗方法的引入，以往被认为病情过重无法进行手术的患者现在可以得到治疗。主动脉瓣或二尖瓣疾病的经皮治疗已成为标准治疗方法。同样，三尖瓣疾病的经皮治疗选择也取得了令人鼓舞的结果，目前仍在深入研究中。
